Dr Shaji Kumar speaks to ecancer about the results of the ENDURANCE trial that were presented at the ASCO 2020 Virtual Meeting.
The trial looks at carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM).
Dr Kumar reports that while KRd was found to be effective for initial therapy there was no advantage to using it over VRd, which remains the current standard of care for these patients.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.